Sionna Therapeutics Secures Exclusive Worldwide Rights To Develop And Commercialize AbbVie's CF Compounds ABBV-2222
Portfolio Pulse from Benzinga Newsdesk
Sionna Therapeutics has secured exclusive worldwide rights to develop and commercialize AbbVie's CF compounds ABBV-2222, ABBV-3067, and ABBV-2851. Phase 2 studies show clinical efficacy, and Sionna's NBD1 stabilizers combined with these compounds demonstrate potential for superior efficacy. AbbVie will receive an upfront payment, equity investment, and is eligible for milestones and royalties.
July 16, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AbbVie has granted Sionna Therapeutics exclusive worldwide rights to develop and commercialize its CF compounds ABBV-2222, ABBV-3067, and ABBV-2851. AbbVie will receive an upfront payment, equity investment, and is eligible for milestones and royalties.
The partnership with Sionna Therapeutics and the promising Phase 2 results of the CF compounds are likely to positively impact AbbVie's stock in the short term. The financial benefits from upfront payments, equity investment, and potential milestones and royalties add to the positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100